MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling by Engelman, Jeffrey A, Zejnullahu, Kreshnik, Mitsudomi, Tetsuya, Song, Youngchul, Hyland, Courtney, Park, Joon Oh, Lindeman, Neal, Gale, Christopher-Michael, Zhao, Xiaojun, Christensen, James, Kosaka, Takayuki, Holmes, Alison J, Rogers, Andrew M, Cappuzzo, Federico, Mok, Tony, Lee, Charles, Johnson, Bruce E, Cantley, Lewis C, Jänne, Pasi A

Get full text

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib by ENGELMAN, Jeffrey A, ZEJNULLAHU, Kreshnik, ALTHAUS, Irene W, GANDHI, Leena, SHAPIRO, Geoffrey I, NELSON, James M, HEYMACH, John V, MEYERSON, Matthew, WONG, Kwok-Kin, JÄNNE, Pasi A, GALE, Christopher-Michael, LIFSHITS, Eugene, GONZALES, Andrea J, SHIMAMURA, Takeshi, FENG ZHAO, VINCENT, Patrick W, NAUMOV, George N, BRADNER, James E

Get full text

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer by Engelman, Jeffrey A, Mukohara, Toru, Zejnullahu, Kreshnik, Lifshits, Eugene, Borrás, Ana M, Gale, Christopher-Michael, Naumov, George N, Yeap, Beow Y, Jarrell, Emily, Sun, Jason, Tracy, Sean, Zhao, Xiaojun, Heymach, John V, Johnson, Bruce E, Cantley, Lewis C, Jänne, Pasi A

Get full text

D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors by Engelman, Jeffrey A., Zejnullahu, Kreshnik, Mitsudomi, Tetsuya, Hyland, Courtney, Oh Park, Joon, Lindeman, Neal, Gale, Christopher-Michael, Zhao, Xiaojun, Christensen, James, Rogers, Rogers M., Cappuzzo, Federico, Mok, Tony, Lee, Charles, Bruce, Johnson E., Cantley, Lewis C., Jänne, Pasi A.

Get full text